ReviewSurgery in practice and science2022
Hemoglobin-based oxygen carriers: Clinical application of HBOC-201 as an alternative to red blood cells for machine perfusion in liver transplantation.
Review in Surgery in practice and science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Reduction in Red Blood Cell Lysis by Polymer Intervention During Rodent Liver Normothermic Machine Perfusion.Transplantation direct · 2026Article
- Real-time monitoring of mitochondrial oxygenation during machine perfusion using resonance Raman spectroscopy predicts organ function.Scientific reports · 2024Article
- Real-time monitoring of mitochondrial oxygenation during machine perfusion using resonance Raman spectroscopy predicts organ function.Research square · 2023Article
- Pushing the boundaries of innovation: the potential ofFrontiers in cardiovascular medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liver transplantation is the gold standard treatment option for end-stage liver diseases and failure. In recent years, ex vivo liver machine perfusion has been introduced to resuscitate livers before transplantation. The RBC-based solution is the main perfusate for this matter. Due to logistic and functional limitations in order to use an RBC-based solution, Hemoglobin-based oxygen carrier-201 (HBOC-201) is the new perfusion solution that is introduced to replace the RBC-based solution. Methods: A systematic literature search of the PubMed registry was performed. A three-stage independent screening method was applied. Inclusion criteria for this review were published prospective, retrospective, clinical trials, and systematic reviews studies using acellular hemoglobin as a perfusion solution. Results: Five studies that used HBOC-201 as the perfusate solution were identified. The overall number of livers that were resuscitated with HBOC-201 perfusate in all the studies was 50 livers. These studies have demonstrated the efficacy of HBOC-201 perfusate in terms of liver post perfusion metabolic and function assessment. Two studies compared HBOC-201 and PRBC as the perfusate solution. One study found comparable outcomes when HBOC-201 was used as the perfusate solution and in the other study, not only the results were comparable, but also, the study showed livers perfusate with HBOC-201 based solution had higher ATP levels, higher bile production, and quicker lactate reduction, and significantly lower ALT level at the end of MP. Conclusion: Machine perfusion (MP) was introduced as an alternative preservation strategy in transplantation. The perfusion solution used in MP is a key factor in the process of organ revitalization, preventing hemolysis, and providing near-to-body physiologic hemostasis. HBOC-201 is a safe and convenient alternative to packed red blood cells in organ perfusion and recent studies showed promising results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.